Szejtli (1998). Introduction and general overview of cyclodextrin chemistry, Chemical Reviews 98(5):1743-54.
Tongiani et al. (2009). Sulfobutyl ether‐alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. Journal of Pharmaceutical Sciences, 98(12):4769-80.
Merzlikine et al. (2011). Development of machine learning models of β-cyclodextrin and sulfobutylether-β-cyclodextrin complexation free energies. International Journal of Pharmaceutics, 418(2):207-16.
Irie et al. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological Issues and Safety Evaluation. Journal of Pharmaceutical Sciences, 86(2):147-62.
Zia et al. (1997). Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether β‐cyclodextrins with steroids. Journal of Pharmaceutical Sciences, 86(2):220-4.
Tong et al. (2018). Preparation and characterization of Berberine Hydrochloride and Trimethoprim Chitosan/ SBE-β-CD microspheres. Journal of Drug Delivery and Technology, 48:300-10.
Li et al. (2011). Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation. Journal of Pharmacy and Pharmacology, 63(6):765-73.
Cui et al (2011). Development of PEGylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: Is improved drug retention sufficient to surpass DSPE-PEG‐induced drug leakage. Journal of Pharmaceutical Sciences, 100(7):2835-48.
Okimoto et al. (1999). Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE) 7m-β-CD. Pharmaceutical Research, 16(4):549-54.
Yildiz et al. (2017). Polymer-free electrospun nanofibers from sulfobutyl ether-β-cyclodextrin (SBE-βCD) inclusion complex with sulfisoxazole: Fast-dissolving and enhanced water-solubility of sulfisoxazole. International Journal of Pharmaceutics, 531(2):550-8.
Järvinen et al. (1995). Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. Journal of Ocular Pharmacology and Therapeutics, 11(2):95-106.